Atara Biotherapeutics Files 8-K: Director Changes & Officer Compensation Updates
Ticker: ATRA · Form: 8-K · Filed: Mar 31, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: ATRA
TL;DR
ATRA board shakeup and exec pay changes filed. Watch for new strategy.
AI Summary
On March 25, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a departure of directors and the election of new ones, alongside updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect future performance and strategy.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- March 25, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the departure of directors and the election of new directors, though specific names are not detailed in the provided excerpt.
What is the nature of the updates to compensatory arrangements?
The filing states there are updates to the compensatory arrangements of certain officers, but the specifics of these arrangements are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 25, 2025.
What is Atara Biotherapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).